HomeOtheratai Life Sciences to Participate in September Investor Events

atai Life Sciences to Participate in September Investor Events

Published on

Disclaimer

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September:


  • Citi’s 17


    th


    Annual BioPharma Conference in Boston
    Format: Industry PanelDate and Time: Wednesday, September 7

    th

    , 10:30 a.m. ET – 11:15 a.m. ETConference Link:

    URL

  • H.C. Wainwright’s 24


    th


    Annual Global Investment Conference in New York City
    Format: Company PresentationDate and Time: Tuesday, September 13

    th

    , 11:00 a.m. ET – 11:45 a.m. ETConference Link:

    URL

  • Cowen’s 2


    nd


    Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
    Format: Industry PanelDate and Time: Monday, September 19

    th

    , 3:05 p.m. ET – 4:05 p.m. ET | 4:15 p.m. ET – 5:15 p.m. ETConference Link:

    URL

  • Jefferies’ 1


    st


    Annual Psychedelics/Emerging Novel Treatments for Mental Health Summit in New York City
    Format: Company PresentationDate and Time: Thursday, September 22

    nd

    , 9:30 a.m. ET – 10:15 a.m. ETLink: TBA

The presentations and archived webcasts will also be accessible in the

Events

section of atai’s website where they will be available for up to 90 days.


About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit

www.atai.life


Forward-Looking Statements

These presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any expressed or implied statements contained in these presentations that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as updated by our subsequent filings with the SEC, as such factors may be updated from time to time in atai’s other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.


Contact Information


Investor Contact:

Stephen Bardin

Chief Financial Officer, atai Life Sciences

Email: [email protected]


Media Contact:

Allan Malievsky

Senior Director, External Affairs

Email: [email protected]

ti?nf=ODY0MTU1NSM1MTM4NjM5IzIyMDY1ODk= atai Life Sciences to Participate in September Investor Events


Primary Logo

Latest News

MindMed Announces Pricing of Public Offering of Common Shares and Warrants

This Post Was Syndicated Under License Via QuoteMedia   Canada NewsWire NEW YORK , Sept. 27, 2022 /CNW/ -- Mind...

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

This Post Was Syndicated Under License Via QuoteMedia - atai’s wholly owned subsidiary, EmpathBio, has...

MindMed Announces Proposed Public Offering of Common Shares

This Post Was Syndicated Under License Via QuoteMedia   Canada NewsWire NEW YORK , Sept. 27, 2022 /CNW/ -- Mind...

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

This Post Was Syndicated Under License Via QuoteMedia   Canada NewsWire First-in-human trial to investigate the tolerability,...

More like this

Red Light Holland Reports First Quarter 2022 Financial Results

Disclaimer Cash balance of $23.0 million as at June 30, 2022 Revenue of $785...

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Canada NewsWire NEW YORK , Aug. 25, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the "Company"...

Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson’s Research for SLS-004

Disclaimer   PR Newswire SLS-004 Utilizes CRISPR-dCas9 to Target the SNCA Gene Responsible for the Expression of Alpha-Synuclein NEW...

Healthy Extracts Reports Record Second Quarter 2022, Net Revenue up 93% with Strong Subscription-Based Revenue Growth

Disclaimer LAS VEGAS, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator...

Red Light Holland to Acquire Two Wellness Shops in the Netherlands: SmartShop Utrecht and SmartShop OSS

Acquisition of SmartShops provide Red Light Holland with full vertical integration from production, packaging,...

MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

  Canada NewsWire NEW YORK , Aug. 2, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED),...